Evaluating iron status and the risk of anemia in young infants using erythrocyte parameters

Pediatr Res. 2013 Feb;73(2):214-20. doi: 10.1038/pr.2012.162. Epub 2012 Nov 20.

Abstract

Background: Correct evaluation of iron status is important in young infants because both iron deficiency and excess may have negative effects on development, growth, and morbidity.

Methods: We evaluated iron status using erythrocyte parameters, including reticulocyte hemoglobin content (CHr) in infants with birth weight <3,000 g (n = 80). Blood samples and infant characteristics were recorded at 6 wk and at 4 and 6 months. Infants with a birth weight ≤2,500 g (n = 36) were recommended for iron supplementation.

Results: Despite a significantly poorer status at 6 wk, iron-supplemented infants had significantly higher hemoglobin level (Hb): 12.2 (SD = 0.8) g/dl and CHr: 28.3 (SD = 1.4) pg at 6 mo, as compared with nonsupplemented infants, Hb: 11.7 (SD = 1.0) g/dl, P = 0.02 and CHr: 26.5 (SD = 2.5) pg, P < 0.001. Prolonged exclusive breastfeeding, high weight gain, and male gender were the predisposing factors for a low iron status at 6 mo. A CHr cutoff level of 26.9 pg at 4 mo proved to be a sensitive predictor for anemia at 6 mo.

Conclusion: Signs of an iron-restricted erythropoiesis were observed in nonsupplemented infants (birth weight 2,501-3,000 g), and CHr was a useful tool for evaluating iron status. The need for iron supplementation in certain infant risk populations should be further evaluated.

Trial registration: ClinicalTrials.gov NCT01201005.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia, Iron-Deficiency / blood
  • Anemia, Iron-Deficiency / diagnosis*
  • Anemia, Iron-Deficiency / drug therapy
  • Anemia, Iron-Deficiency / etiology
  • Biomarkers / blood
  • Birth Weight
  • Breast Feeding
  • Chi-Square Distribution
  • Dietary Supplements
  • Erythrocyte Count
  • Erythrocyte Indices
  • Erythrocytes / drug effects
  • Erythrocytes / metabolism*
  • Erythropoiesis / drug effects
  • Female
  • Ferrous Compounds / therapeutic use
  • Hemoglobins / metabolism
  • Humans
  • Infant
  • Infant, Low Birth Weight / blood*
  • Infant, Newborn
  • Iron / blood*
  • Male
  • Nonlinear Dynamics
  • Norway
  • Predictive Value of Tests
  • Prognosis
  • Reticulocytes / metabolism
  • Risk Factors
  • Sex Factors
  • Time Factors
  • Weight Gain

Substances

  • Biomarkers
  • Ferrous Compounds
  • Hemoglobins
  • Iron
  • ferrous fumarate

Associated data

  • ClinicalTrials.gov/NCT01201005